Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReChiVe bladder preservation with neoadjuvant intensified MVAC
2009-014264-19Phase 2Active
- Sponsor
- Clinique Mutualiste Chirurgicale de la Loire
- Start
- Nov 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, vinblastine, doxorubicin, cisplatin and lenograstim in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC), sponsored by Clinique Mutualiste Chirurgicale de la Loire. Primary endpoint: 5-year bladder preservation rate. Started Nov 2009; status: active.
02
Drugs
methotrexatevinblastinedoxorubicincisplatinlenograstim
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2009-014264-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014264-19.